COMMUNIQUÉS West-GlobeNewswire

T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
16/09/2024
Expands available market to include over 200 children’s hospitals in the United States LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid [...]
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
16/09/2024
Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth [...]
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16/09/2024
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx ® (cabozantinib) versus placebo in advanced pancreatic and extra-pancreatic [...]
Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
16/09/2024
Les données ont démontré une réduction significative, tant sur le plan statistique que sur le plan clinique, du risque de progression de la maladie ou de décès avec Cabometyx ® (cabozantinib) par rapport au placebo dans [...]
NeuroStar® Releases Software Upgrades to Elevate Patient Care
16/09/2024
Upgrades improve communication, streamline data management, and strengthen security MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, [...]
Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients
16/09/2024
In the US pivotal trial, WRAPSODY achieved 89.8% target lesion primary patency at 6 months SOUTH JORDAN, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare [...]
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
16/09/2024
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical [...]
BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research
16/09/2024
Partnership increases physician and patient participation in clinical trials GRAND RAPIDS, Mich. and SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BAMF Health, a world leader in molecular imaging and Theranostics [...]
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16/09/2024
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for [...]
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
16/09/2024
September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant Funds to Advance Development of Phase 3 Asset Biodexa Pharmaceuticals [...]
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16/09/2024
Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
15/09/2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1 Injected and non- [...]
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
15/09/2024
Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses [...]
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
15/09/2024
Trial investigating Cabometyx ® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet statistical [...]
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
15/09/2024
L’essai portant sur Cabometyx ® (cabozantinib) en association avec l’atézolizumab a démontré une tendance positive à l’amélioration de l’un des critères d’évaluation principaux de la survie globale, sans atteindre la [...]
KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions
15/09/2024
RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is cementing its position as a global leader in healthcare, evidenced by remarkable growth in [...]
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
15/09/2024
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET imaging is required to [...]
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15/09/2024
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with [...]
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15/09/2024
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of [...]

Pages